Table 1.
Baseline clinical details.
| Study cohort, n = 64 | |||
| Variable | INR, n = 17 | IR, n = 47 | P value |
| Age (years) | 44 (39–55) | 38 (34–50) | 0.075 |
| Male (%) | 76.5 | 78.7 | 1.000 |
| BMI (kg/m2) | 22.9 (21.5–23.4) | 23 (20.8–24.2) | 0.967 |
| AIDS (%) | 100.0 | 85.1 | 0.175 |
| HIV-1 risk factor (%) | |||
| Injecting drug user | 0.0 | 8.5 | 0.566 |
| Homosexual | 47.1 | 44.7 | 1.000 |
| Heterosexual | 41.2 | 42.6 | 1.000 |
| Other/unknown | 11.8 | 4.3 | 0.285 |
| CD4+ T-cell count (cells/μl) | |||
| Baseline | 60 (28–122) | 92 (48–166) | 0.068 |
| At 36 months after ART | 188 (117–219) | 378 (323–469) | <0.001 |
| Plasma viral load (log copies/ml) | |||
| Baseline | 5.5 (4.8–5.7) | 5.4 (4.8–5.7) | 0.915 |
| At 36 months after ART | 1.3 (1.3–1.7) | 1.3 (1.3–1.6) | 0.355 |
| ART received (%) | |||
| 2NRTi + NNRTi | 47.1 | 42.6 | 0.782 |
| 2NRTi + PI | 52.9 | 57.4 | 0.782 |
Quantitative variables are expressed as median (interquartile range). Qualitative variables are expressed as percentages. AIDS was diagnosed according to the CDC1993 criteria. ART, antiretroviral treatment; INR, immunological nonresponders; IR, immunological responders; NRTi, nucleoside reverse transcriptase inhibitors; NNRTi, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.